Operator

Good day, ladies and gentlemen, and welcome to NeuroOne Medical Technologies Corporation's Second Quarter Fiscal 2026 Financial Results Conference Call. Today's call will be conducted by the company's Chief Executive Officer, Dave Rosa; and Ron McClurg, the company's Chief Financial Officer.

Before I turn the call over to Mr. Rosa, I'd like to remind you that this conference call will include forward-looking statements within the meaning of U.S. federal securities laws with respect to future operations, financial results, including events, trends and performance, which are based on management's beliefs and assumptions as of today's call.

Forward-looking statements may involve known and unknown risks, uncertainties and other factors, which may cause results -- actual results to differ materially from those expressed or implied by such statements.

See NeuroOne's financial results press release and SEC filings for information regarding specific risks and uncertainties that could cause actual results to differ. Except as required by law, NeuroOne undertakes no obligation to update such forward-looking statements.

With that, I will turn the call over to Mr. Dave Rosa, Chief Executive Officer of NeuroOne. Please go ahead, sir.

David Rosa
President, CEO & Director

Thank you, operator, and thank you to everyone for joining us today. I'd like to welcome you to our second quarter fiscal 2026 financial results conference call. Product revenue for the OneRF brain ablation system in the second quarter of fiscal 2026 grew 72% year-over-year to $2.4 million compared to $1.4 million in the second quarter of fiscal 2025.